Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome-Reference-Cited by-同舟云学术

Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome

Published:2021-04 Issue:15 Volume:127 Page:2657-2665
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Palandri Francesca¹^ORCID,Tiribelli Mario²^ORCID,Breccia Massimo³^ORCID,Bartoletti Daniela¹⁴^ORCID,Elli Elena M.⁵,Benevolo Giulia⁶^ORCID,Martino Bruno⁷,Cavazzini Francesco⁸,Tieghi Alessia⁹,Iurlo Alessandra¹⁰^ORCID,Abruzzese Elisabetta¹¹^ORCID,Pugliese Novella¹²^ORCID,Binotto Gianni¹³,Caocci Giovanni¹⁴,Auteri Giuseppe¹⁴^ORCID,Cattaneo Daniele¹⁰,Trawinska Malgorzata M.¹¹,Stella Rossella²,Scaffidi Luigi¹⁵,Polverelli Nicola¹⁶,Micucci Giorgia¹⁷,Masselli Elena¹⁸,Crugnola Monica¹⁸,Bosi Costanza¹⁹,Heidel Florian H.²⁰,Latagliata Roberto²¹^ORCID,Pane Fabrizio¹²,Cuneo Antonio⁸,Krampera Mauro¹⁵,Semenzato Gianpietro¹³,Lemoli Roberto M.²²²³,Cavo Michele¹⁴,Vianelli Nicola¹^ORCID,Bonifacio Massimiliano¹⁵,Palumbo Giuseppe A.²⁴^ORCID

Affiliation:

1. Istituto di Ematologia “Seràgnoli,” IRCCS Azienda Ospedaliero–Universitaria di Bologna Bologna Italy

2. Division of Hematology and Bone Marrow Transplantation Azienda Sanitaria Universitaria Integrata di Udine Udine Italy

3. Division of Cellular Biotechnologies and Hematology University Sapienza Rome Italy

4. Dipartimento di Medicina Specialistica Diagnostica e Sperimentale Università di Bologna Bologna Italy

5. Hematology Division and Bone Marrow Unit San Gerardo Hospital, Azienda Socio Sanitaria Territoriale Monza Monza Italy

6. Division of Hematology Città della Salute e della Scienza Hospital Turin Italy

7. Division of Hematology Azienda Ospedaliera “Bianchi Melacrino Morelli” Reggio Calabria Italy

8. Division of Hematology University of Ferrara Ferrara Italy

9. Department of Hematology Azienda Unità Sanitaria Locale‐IRCCS di Reggio Emilia Reggio Emilia Italy

10. Hematology Division Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy

11. Division of Hematology Ospedale S. Eugenio Rome Italy

12. Department of Clinical Medicine and Surgery Federico II University Medical School Naples Italy

13. Unit of Hematology and Clinical Immunology University of Padua Padua Italy

14. Ematologia Ospedale Businco, Università degli Studi di Cagliari Cagliari Italy

15. Section of Hematology University of Verona Verona Italy

16. Unit of Blood Diseases and Stem Cell Transplantation Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Brescia Italy

17. Hematology and Stem Cell Transplant Center Azienda Ospedaliera Ospedali Riuniti Marche Nord Pesaro Italy

18. Department of Medicine and Surgery University of Parma Parma Italy

19. Division of Hematology AUSL di Piacenza Piacenza Italy

20. Hematology and Oncology Friedrich Schiller University Medical Center Jena Germany

21. Hematology Unit Ospedale Belcolle Viterbo Italy

22. Clinic of Hematology Department of Internal Medicine University of Genoa Genoa Italy

23. IRCCS Policlinico San Martino Genova Italy

24. Department of Scienze Mediche Chirurgiche e Tecnologie Avanzate “G. F. Ingrassia,” University of Catania Italy

Funder

Associazione Italiana Contro le Leucemie - Linfomi e Mieloma

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33541

Reference35 articles.

1. Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

2. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

3. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

4. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

5. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Comparative efficacy and hematologic safety of different dosages of JAK inhibitors in the treatment of myelofibrosis: a network meta-analysis;Frontiers in Oncology;2024-08-30

3. Would you like to take some more ruxolitinib after your fedratinib?;British Journal of Haematology;2024-08-14

4. Successful ruxolitinib rechallenge after fedratinib failure in a patient with overt myelofibrosis;Annals of Hematology;2024-08-02

5. Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real‐world case series;British Journal of Haematology;2024-07-17